Search Results
You are looking at 21 - 23 of 23 items for
- Author: I. Huhtaniemi x
- Refine by access: All content x
Search for other papers by K Hakola in
Google Scholar
PubMed
Search for other papers by AM Haavisto in
Google Scholar
PubMed
Search for other papers by DD Pierroz in
Google Scholar
PubMed
Search for other papers by A Aebi in
Google Scholar
PubMed
Search for other papers by A Rannikko in
Google Scholar
PubMed
Search for other papers by T Kirjavainen in
Google Scholar
PubMed
Search for other papers by ML Aubert in
Google Scholar
PubMed
Search for other papers by I Huhtaniemi in
Google Scholar
PubMed
We have previously described the preparation, purification and partial characterization of recombinant (rec) forms of rat luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In the present study, the special functional features of these hormones were studied further, in vitro and in vivo, and compared with human recLH and recFSH, as well as with human urinary choriongonadotropin (hCG) and rat pituitary LH (NIDDK-RP3). In radioreceptor assay, the affinity of hCG binding to rat testis membranes was 5-fold higher than that of human recLH and 100-fold higher than that of rat recLH. In in vitro bioassay, using dispersed adult mouse interstitial cells or a mouse Leydig tumor cell line (BLT-1), hCG and human recLH were 10- to 20-fold more potent than rat recLH. Correspondingly, rat pituitary LH was about 10-fold less potent than rat recLH, and evoked a maximum testosterone response that was about half of that elicited by the other LH/CG preparations. Rat recFSH was about 10-fold less potent than human recFSH in stimulating cAMP production of a mouse Sertoli cell line (MSC-1) expressing the recombinant rat FSH receptor. The circulating half-times (T1/2) of rat and human rec hormones were assessed after i.v. injections into adult male rats rendered gonadotropin-deficient by treatment with a gonadotropin-releasing hormone antagonist. A novel immunometric assay was used for the rat FSH measurements. In the one-component model the T1/2 values of rat and human recLH were 18.2 +/- 1.9 min (n = 7) and 44.6 +/- 3.1 min (n = 7) respectively and those of rat and human recFSH were 88.4 +/- 10.7 min (n = 6) and 55.0 +/- 4.2 min (n = 6) respectively; the two-component models revealed similar differences between the rec hormone preparations. Collectively, rat recLH was eliminated significantly faster from the circulation than human recLH (P < 0.0001). In contrast, the elimination of rat recFSH was significantly slower than that of human recFSH (P = 0.02). In conclusion, rat recFSH and rat recLH display lower biopotencies per unit mass than the respective human hormones in vitro, and also in vivo for LH. This is paralleled by shorter T1/2 of rat recLH than the respective human hormone in the circulation, whereas human recFSH has a shorter T1/2 than human FSH. The special functional features of the rat rec gonadotropins emphasize the use of these preparations on studies of gonadotropin function in the rat, an important animal model for reproductive physiology.
Search for other papers by M Tena-Sempere in
Google Scholar
PubMed
Search for other papers by PR Manna in
Google Scholar
PubMed
Search for other papers by FP Zhang in
Google Scholar
PubMed
Search for other papers by L Pinilla in
Google Scholar
PubMed
Search for other papers by LC Gonzalez in
Google Scholar
PubMed
Search for other papers by C Dieguez in
Google Scholar
PubMed
Search for other papers by I Huhtaniemi in
Google Scholar
PubMed
Search for other papers by E Aguilar in
Google Scholar
PubMed
Leptin, the product of the ob gene, is a pivotal signal in the regulation of neuroendocrine function and fertility. Although much of the action of leptin in the control of the reproductive axis is exerted at the hypothalamic level, some direct effects of leptin on male and female gonads have also been reported. Indeed, recent evidence demonstrated that leptin is able to inhibit testosterone secretion at the testicular level. However, the molecular mechanisms behind this effect remain unclear. The focus of this study was twofold: (1) to identify potential targets for leptin-induced inhibition of steroidogenesis, and (2) to characterize in detail the pattern of expression and cellular distribution of leptin receptor (Ob-R) mRNA in adult rat testis. In pursuit of the first goal, slices of testicular tissue from adult rats were incubated with increasing concentrations of recombinant leptin (10(-9)--10(-7 )M) in the presence of human chorionic gonadotropin (hCG; 10 IU/ml). In this setting, testosterone secretion in vitro was monitored, and expression levels of mRNAs encoding steroidogenic factor 1 (SF-1), steroidogenic acute regulatory protein (StAR), cytochrome P450 cholesterol side-chain cleavage enzyme (P450 scc) and 17 beta-hydroxysteroid dehydrogenase type III (17 beta-HSD) were assessed by Northern hybridization. In pursuit of the second goal, the pattern of cellular expression of the Ob-R gene in adult rat testis was evaluated by in situ hybridization using a riboprobe complementary to all Ob-R isoforms. In addition, testicular expression levels of the different Ob-R isoforms, previously identified in the hypothalamus, were analyzed by means of semi-quantitative RT-PCR. In keeping with our previous data, recombinant leptin significantly inhibited hCG-stimulated testosterone secretion. In this context, leptin, in a dose-dependent manner, was able to co-ordinately decrease the hCG-stimulated expression levels of SF-1, StAR and P450 scc mRNAs, but it did not affect those of 17 beta-HSD type III. In situ hybridization analysis showed a scattered pattern of cellular expression of the Ob-R gene within the adult rat testis, including Leydig and Sertoli cells. In addition, assessment of the pattern of expression of Ob-R subtypes revealed that the long Ob-Rb isoform was abundantly expressed in adult rat testis. However, variable levels of expression of Ob-Ra, Ob-Re, and Ob-Rf mRNAs were also detected, whereas those of the Ob-Rc variant were nearly negligible. In conclusion, our results indicate that decreased expression of mRNAs encoding several up-stream elements in the steroidogenic pathway may contribute, at least partially, to leptin-induced inhibition of testicular steroidogenesis. In addition, our data on the pattern of testicular expression of Ob-R isoforms and cellular distribution of Ob-R mRNA may help to further elucidate the molecular mechanisms of leptin action in rat testis.
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by M S Fernandes in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by V Pierron in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by D Michalovich in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by S Astle in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by S Thornton in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by H Peltoketo in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by E W-F Lam in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by B Gellersen in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by I Huhtaniemi in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by J Allen in
Google Scholar
PubMed
Inpharmatica Ltd, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
Biomedical Research Institute, Department of Biological Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
Cancer Research-UK Labs and Section of Cancer Cell Biology, Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
Endokrinologikum Hamburg, Falkenried 88, 20251 Hamburg, Germany
Search for other papers by J J Brosens in
Google Scholar
PubMed
Rapid non-genomic actions of progesterone are implicated in many aspects of female reproduction. Recently, three human homologues of the fish membrane progestin receptor (mPR) have been identified. We combined bioinformatic analysis with expression profiling to define further the role of these mPRs in human reproductive tissues. Sequence analysis confirmed that the mPRs belong to a larger, highly conserved family of proteins, termed ‘progestin and adiponectin receptors’ (PAQRs). A comparison of the expression of mPR transcripts with that of two related PAQR family members, PAQRIII and PAQRIX, in cycling endometrium and pregnancy tissues revealed markedly divergent expression levels and profiles. For instance, endometrial expression of mPRα and γ and PAQRIX was cycle-dependent whereas the onset of parturition was associated with a marked reduction in myometrial mPRα and β transcripts. Interestingly, mPRα and PAQRIX were most highly expressed in the placenta, and the tissue expression levels of both genes correlated inversely with that of the nuclear PR. Phylogenetic analysis demonstrated that PAQRIX belongs to the mPR subgroup of proteins. We also validated a polyclonal antibody raised against the carboxy-terminus of human mPRα. Immunohistochemical analysis demonstrated more intense immunoreactivity in placental syncytiotrophoblasts than in endometrial glands or stroma. The data suggest important functional roles for mPRα, and possibly PAQRIX, in specific reproductive tissues, particularly those that express low levels of nuclear PR.